Skip to main content
SpringerLink
Log in

Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Benkert O, Hippius H (2005) Kompendium der Psychiatrischen Pharmakotherapie. Springer Medizin, Heidelberg

    Google Scholar 

  2. Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P (2002) The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 35:50–56

    Article  PubMed  CAS  Google Scholar 

  3. Bork JA, Rogers T, Wedlund PJ, de Leon J (1999) A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 60:469–476

    Article  PubMed  CAS  Google Scholar 

  4. Christensson EG (1989) Pharmacological data of the atypical neuroleptic compound melperone (Buronil). Acta Psychiatr Scand (Suppl) 352:7–15

    Article  CAS  Google Scholar 

  5. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66:15–27

    Article  PubMed  Google Scholar 

  6. Eap CB, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, Jonzier-Perey M, Baumann P (2001) Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit 23:228–231

    Article  PubMed  CAS  Google Scholar 

  7. Ereshefsky L (1996) Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 57(suppl 11):12–25

    PubMed  CAS  Google Scholar 

  8. Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Hartter S (2003) Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry 36:3–6

    Article  PubMed  Google Scholar 

  9. Huang ML, van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z, Visscher HW, Jonkman JH (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257–268

    Article  PubMed  CAS  Google Scholar 

  10. Köhnke MD, Griese EU, Stösser D, Gaertner I, Barth G (2002) Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 35:116–118

    Article  PubMed  Google Scholar 

  11. Kretzschmar R, Otto J, Teschendorf HJ, Worstmann W (1976) Pharmacological investigations of 4′-fluoro-4-(4-methyl-peperidono)-butyrophenone with respect to its sedative and sleep-inducing properties. Arzneimittelforschung 26:1073–1076

    PubMed  CAS  Google Scholar 

  12. Lessard E, Yessine MA, Hamelin BA, O’Hara G, LeBlanc J, Turgeon J (1999) Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9:435–443

    Article  PubMed  CAS  Google Scholar 

  13. Van Beijsterveldt LEC, Geerts RJF, Leysen JE, Megens AAHP, Van den Eynde HMJ, Meuldermans WEG, Heykants JJ (1994) The regional brain distribution of risperidone and its active metabolite 9;hydroxyrisperidone in the rat. Psychopharmacology 114:53–62

    Article  PubMed  Google Scholar 

  14. Veefkind AH, Haffmans PM, Hoencamp E (2000) Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22:202–208

    Article  PubMed  CAS  Google Scholar 

  15. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G (2001) Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29:1263–1268

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital of Psychiatry and Psychotherapy, Tübingen University Hospital, 72076, Tübingen, Germany

    Michael D. Köhnke, Ulrich Lutz, Gerlinde Wiatr, Frank Schwärzler, Bastian Weller, Klaus Schott & Gerhard Buchkremer

Authors
  1. Michael D. Köhnke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerlinde Wiatr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frank Schwärzler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bastian Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Klaus Schott
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gerhard Buchkremer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael D. Köhnke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Köhnke, M.D., Lutz, U., Wiatr, G. et al. Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone. Eur J Clin Pharmacol 62, 333–334 (2006). https://doi.org/10.1007/s00228-006-0098-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-006-0098-y

Keywords

Search

Navigation